Company Short-Term Debt: fulgentgenetics.com (FLGT)

Public company logo of Fulgent Genetics (FLGT)

Fulgent Genetics, Inc. (FLGT) maintains an impeccable reputation among oncologists due to its precise bioinformatic analysis and rapid turnaround times for results. This price chart, which assists in the basic asset valuation, shows that the individual short-term debt metric is 0.00. The business relies on its own sequencing equipment, enabling the immediate expansion of its test menu. High efficiency is achieved through the near-total automation of sample preparation and robotic data processing.

FLGT (Fulgent Genetics) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Fulgent (FLGT)

- stock price and consensus target price:
Stock Price Fulgent Genetics|FLGT - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value Fulgent Genetics, Inc.|FLGT - Business Value
- shareholders' equity book value data:
Book Value per Share Fulgent Genetics|FLGT - Book Capitalization|Market Value to Book Value Ratio fulgentgenetics.com|FLGT - Aggregate Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Fulgent Genetics, Inc.|FLGT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Fulgent Genetics, Inc.|FLGT - Company Total Debt Obligations|Debts to Book Capitalization Fulgent Genetics, Inc.|FLGT - Long-Term Debt Volume|Company Short-Term Debt Fulgent Genetics|Quick Ratio fulgentgenetics.com
- net income and valuation multiples indicators:
FLGT - Profit After Tax
Fundamental company analysis:Fulgent Genetics (FLGT)
Flagship merchandise of Fulgent Genetics, Inc.

Short-term debt records the aggregate of all financial obligations due within the coming year. Analyzing current debt on loans and borrowings allows for an assessment of liquidity and default risk over the short term. This metric sums current loans and notes, reflecting the pressure on working capital. For Fulgent Genetics, Inc. (FLGT), the absence of such encumbrances confirms financial stability. This strengthens the operating margin through the effective utilization of the AI stack in diagnostics.

Competitors of Fulgent Genetics, Inc.

Agilent - Company Short-Term Debts|DGX - Company Short-Term Debts|Illumina Corp (ILMN) - Company Short-Term Debt|Company Short-Term Indebtedness EXAS|RVTY (Revvity, Inc.) - Company Short-Term Debts|Company Short-Term Debts bio-rad.com|Company Short-Term Debt Anbio (NNNN)|Company Short-Term Debt SHC (Sotera Health Corp)|QuidelOrtho Corp - Company Current Liabilities|OPKO Health Corp. (OPK) - Short-Term Debt|CDNA - Company Short-Term Debt|Short-Term Debt Volume maravai.com MRVI|LAB: Company Short-Term Debts|CTKB - Short-Term Debt Volume|Company Short-Term Debt OraSure Technologies Inc|Exagen Diagnostics (XGN) - Short-Term Debt Volume|Company Short-Term Debts MDXH|LUCD: Current Liabilities|Prenetics - Company Current Liabilities|Company Short-Term Debts Insight Molecular Diagnostics, Inc. IMDX|TRIB - Company Short-Term Debt|PRPH: Company Short-Term Debt|AIMD: Company Short-Term Debts|Short-Term Indebtedness codiagnostics.com CODX|HSCS (HeartSciences) - Company Short-Term Debts|Short-Term Debt Biomerica Inc. BMRA|Company Short-Term Debt Cardio Diagnostics (CDIO)|Virax Biolabs Corp - Company Short-Term Indebtedness|Bluejay Diagnostics - Company Current Liabilities|Amount of Current Liabilities AWH (aspirawh.com)|AXDX: Company Current Liabilities|Company Short-Term Loans and Borrowings CNTG (CENTOGENE N.V.)|ENZ: Company Short-Term Debts|Short-Term Indebtedness Fresh2 Group FRES|GENE (Genetic Technologies Ltd) - Company Short-Term Debts|Short-Term Debt 23andme.com ME|Company Short-Term Debt Psychemedics Corporation (PMD)